A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

non-alcoholic steatohepatitis (NASH) is an inflammatory liver disease caused by the accumulation of fat in liver cells. With the change of living habits and diet, the incidence of Nash continues to increase. In the early stage, NASH generally has no obvious symptoms. With the progression of the disease and the aggravation of liver damage, it may induce fatigue, loss of body mass, and pain in the right upper abdomen, which seriously affects the health of patients. There are no specific drugs to treat NASH in clinical practice. Increasing exercise, taking drugs to avoid liver damage, controlling diet and other methods can alleviate clinical symptoms to a certain extent, but the stability of disease control is poor, and it is easy to develop into cirrhosis, threatening the life safety of patients. However, there are few clinical reports on the effect of drugs on NASH. In the previous treatment of patients with liver fibrosis, our research group found that non-alcoholic steatohepatitis NASH induced liver fibrosis has a good effect, suggesting that Langqingata may improve NASH. Based on this, this study observed the total effective rate of Lang Qingata in the treatment of nonalcoholic steatohepatic NASH.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shupei Li

Criteria

Inclusion Criteria:

• Inclusion criteria: Participants must meet all of the following criteria to enter the trial.

1. Signed written informed consent;

2. Age 18-60 years old, gender is not limited;

3. Meet the clinical diagnostic criteria for NASH; (See study content 3 Diagnostic criteria)

4. The subjects could follow the follow-up plan, objectively describe the symptoms, and cooperate with the completion of the scale;

5. Non-lactating pregnant women and no pregnancy plan during the test;

6. Do not participate in any clinical trials for 3 months before and during the trial.

Exclusion Criteria:

1. < 18 years old or > 60 years old;

2. People who are allergic or allergic to the ingredients of this medicine;

3. Liver cirrhosis and liver tumor patients or ALT, AST≥ 5 times the normal upper limit, liver function damage is more serious This;

4. Women who are pregnant, breastfeeding or planning to become pregnant during the trial;

5. Complicated with viral hepatitis, alcoholic hepatitis, autoimmune liver disease and cirrhosis, liver cells Patients with other liver diseases such as cancer, serious heart, brain, and kidney diseases, such as chronic cardiac insufficiency;

6. suffering from other serious diseases, such as tumors and other special blood diseases;

7. Poor compliance, unable to cooperate with the completion of the experiment.